After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.

A meta-analysis of six trials (Poseidon) found no overall survival benefit from adding long-course (24 months) hormone therapy to post-operative radiotherapy. It suggests that a shorter course of 4-6 months is adequate for most men, marking a significant shift towards treatment de-escalation to reduce long-term toxicity without compromising efficacy in this specific setting.

In metastatic hormone-sensitive prostate cancer, many patients receive multiple subsequent therapies, making Overall Survival (OS) a difficult endpoint to achieve. Therefore, a large, meaningful improvement in radiographic progression-free survival (RPFS) is considered a critical and actionable outcome for patients.

Unlike bladder cancer, prostate cancer has highly effective androgen-pathway inhibitors (ARPIs) that extend survival. This success has pushed chemotherapy and, by extension, ADC development to later treatment lines as clinicians prioritize other novel mechanisms of action first.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

Despite two positive Phase 3 trials showing an overall survival benefit, Radium-223 is not widely used. A key reason is its failure to produce dramatic PSA declines or clear scan improvements. This lack of a satisfying, immediate feedback signal, or "firework display," makes clinicians less likely to prescribe it, even with proven efficacy.

For antibody-drug conjugates (ADCs) to make a meaningful impact in prostate cancer, the clinical development bar is exceptionally high. Merely showing activity in late-line settings is insufficient; the true measure of success is demonstrating superiority over the established chemotherapy standard, docetaxel.

Despite showing a strong overall survival (OS) advantage in trials, Radium-223 is not widely used. It is considered a "mystery box" because it rarely produces satisfying intermediate results like PSA declines or cleared scans. This parallels adoption challenges faced by other therapies with proven OS but weak surrogate endpoints.

Despite a positive trial endpoint and FDA approval, a GU medical oncologist is not adopting Lutetium-PSMA in the hormone-sensitive prostate cancer setting. He argues the existing therapy is already highly effective, and new treatments must offer a 'revolutionary,' not just an 'evolutionary,' benefit to justify the added toxicity and cost without a clear overall survival advantage.